Investing.com -- Teleperformance (EPA: TEPRF) shares plunged more than 16% on Friday after the company cut its full-year revenue outlook, reported weaker-than-expected margins and missed earnings ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.

Huntington Ingalls Industries (HII) reports $3.1B Q2 revenue, backlog at $56.9B, with enhanced free cash flow guidance.

Huntington Ingalls Industries ( NYSE: HII) shares jumped more than 5% in premarket trading Thursday after the U.S. defense ...

C3.ai (NYSE: AI) is generating accelerating revenue growth and improving free cash flow. It also boasts a pristine balance sheet. Where to invest $1,000 right now? Our analyst team just revealed what ...

M&A is back is in style again under President Donald Trump. That’s good news for investors in stocks such as C3.ai, Viking ...

C3.ai Inc (AI) is winning back investors with a management shake-up that could redefine its future after CEO and founder Tom ...

Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...

C3.ai has the ingredients to build a sustainable enterprise AI business. There are risks that could derail C3.ai's expansion.

Investors are hopeful that C3.ai (NYSE: AI) can deliver results similar to Palantir (NASDAQ: PLTR). *Stock prices used were the afternoon prices of July 23, 2025. The video was published on July 25, ...

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of C3.ai's market ...

The stocks bucked a mostly optimistic broader market, with the tech-heavy Nasdaq and the S&P 500 both up by 0.18 percent and ...